Phase II studies of docetaxel in the treatment of various solid tumours

J. Verweij*, G. Catimel, A. Sulkes, C. Sternberg, I. Wolff, S. Aamdal, Q. van Hoesel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Docetaxel has been evaluated in six tumour types in a total of 189 patients entered into phase II studies. Treatment consisted of a 1 h intravenous infusion of docetaxel 100 mg/m2 repeated every 3 weeks. No premedication was administered for possible hypersensitivity reactions. Docetaxel was found to be effective as first-line chemotherapy for head and neck cancer (response rate 44%) gastric cancer (23%) and melanoma (14%) and as second-line chemotherapy for soft tissue sarcomas (21%; 95% confidence interval: 7.5%-43.7%). The results in colorectal and renal cancer were disappointing, with response rates of less than 10%. The most frequent adverse effects were alopecia (81%), grade III-IV leucocytopenia of short duration (66%) and skin reactions (52%). Hypersensitivity reactions were mild and occurred in 26% of patients. Docetaxel is an important new drug in the treatment of solid tumours.

Original languageEnglish
Pages (from-to)S21-S24
JournalEuropean Journal of Cancer
Issue number1004
StatePublished - Oct 1995
Externally publishedYes


  • docetaxel
  • head and neck neoplasms
  • iatrogenic disease
  • kidney neoplasms
  • melanoma
  • soft tissue neoplasms
  • stomach neoplasms


Dive into the research topics of 'Phase II studies of docetaxel in the treatment of various solid tumours'. Together they form a unique fingerprint.

Cite this